The Trump administration is sparing no expense in finding a cure for the coronavirus evidenced by their recent purchase of 300 million doses of a potential cure still in development by AstraZeneca and Oxford University.
While the cure is not expected to be finished until October, Health and Human Services Secretary Alex Azar described the purchase as a “milestone” in treating the coronavirus.
“This contract with AstraZeneca is a major milestone in Operation Warp Speed’s work toward a safe, effective, widely available vaccine by 2021,” he said via Reuters.
AstraZeneca is awaiting early stage clinical results of its potential COVID-19 vaccine being developed with Oxford University. Having received over $1 billion from the U.S., the British drugmaker said it can deliver a billion doses if tests are successful https://t.co/aA0H9cYu8I pic.twitter.com/Z2xCSylygE
— Reuters (@Reuters) May 21, 2020
Here’s more from the report:
The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to British drugmaker AstraZeneca. Immunity to the new coronavirus is uncertain and so the use of vaccines unclear.
The U.S. deal allows a late-stage – Phase III – clinical trial of the vaccine with 30,000 people in the United States.
AstraZeneca, based in Cambridge, England, said it had concluded agreements for at least 400 million doses of the vaccine and secured manufacturing capacity for one billion doses, with first deliveries due to begin in September.
Now the most valuable company on Britain’s blue-chip FTSE 100 Index, it has already agreed to deliver 100 million doses to people in Britain, with 30 million as soon as September. Ministers have promised that Britain will get first access to the vaccine.